A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease.

Trial Profile

A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects with Alzheimer's Disease.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Pimavanserin (Primary)
  • Indications Aggression; Agitation
  • Focus Adverse reactions
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 28 Feb 2018 Planned number of patients changed from 432 to 111.
    • 28 Feb 2018 Planned End Date changed from 1 Jun 2020 to 1 Aug 2019.
    • 28 Feb 2018 Planned primary completion date changed from 1 May 2020 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top